XML 72 R43.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
Segment Reporting [Abstract] |
Summarized financial information of segments |
| Pharmacy |  | Retail/ |  | Health Care |  | Corporate/ |  | Intersegment |  | Consolidated
In millions | Services (1)(2) |  | LTC (2) |  | Benefits (2) |  | Other |  | Eliminations (2) |  | Totals
2018: |  |  |  |  |  |  |  |  |  |  |
Revenues from customers | $ | 134,115 |  |  | $ | 83,989 |  |  | $ | 5,504 |  |  | $ | 4 |  |  | $ | (29,693 | ) |  | $ | 193,919 |
Net investment income (3) | 13 |  |  | — |  |  | 45 |  |  | 602 |  |  | — |  |  | 660 |
Total revenues | 134,128 |  |  | 83,989 |  |  | 5,549 |  |  | 606 |  |  | (29,693 | ) |  | 194,579 |
Operating income (loss) (4)(5) | 4,699 |  |  | 620 |  |  | 276 |  |  | (805 | ) |  | (769 | ) |  | 4,021 |
Depreciation and amortization | 712 |  |  | 1,698 |  |  | 170 |  |  | 138 |  |  | — |  |  | 2,718 |
Additions to property and equipment | 326 |  |  | 1,350 |  |  | 46 |  |  | 401 |  |  | — |  |  | 2,123 |
2017: |  |  |  |  |  |  |  |  |  |  |
Revenues from customers | 130,596 |  |  | 79,398 |  |  | — |  |  | — |  |  | (25,229 | ) |  | 184,765 |
Net investment income | 5 |  |  | — |  |  | — |  |  | 16 |  |  | — |  |  | 21 |
Total revenues(7) | 130,601 |  |  | 79,398 |  |  | — |  |  | 16 |  |  | (25,229 | ) |  | 184,786 |
Operating income (loss) (4)(5)(7) | 4,657 |  |  | 6,558 |  |  | — |  |  | (936 | ) |  | (741 | ) |  | 9,538 |
Depreciation and amortization | 712 |  |  | 1,651 |  |  | — |  |  | 116 |  |  | — |  |  | 2,479 |
Additions to property and equipment | 311 |  |  | 1,398 |  |  | — |  |  | 340 |  |  | — |  |  | 2,049 |
2016: |  |  |  |  |  |  |  |  |  |  |
Revenues from customers | 119,963 |  |  | 81,100 |  |  | — |  |  | — |  |  | (23,537 | ) |  | 177,526 |
Net investment income | 2 |  |  | — |  |  | — |  |  | 18 |  |  | — |  |  | 20 |
Total revenues(7) | 119,965 |  |  | 81,100 |  |  | — |  |  | 18 |  |  | (23,537 | ) |  | 177,546 |
Operating income (loss) (4)(5)(6)(7) | 4,570 |  |  | 7,437 |  |  | — |  |  | (900 | ) |  | (721 | ) |  | 10,386 |
Depreciation and amortization | 714 |  |  | 1,642 |  |  | — |  |  | 119 |  |  | — |  |  | 2,475 |
Additions to property and equipment | 295 |  |  | 1,732 |  |  | — |  |  | 252 |  |  | — |  |  | 2,279 |
_____________________________________________
(1) | Total revenues of PSS include approximately $11.4 billion, $10.8 billion and $10.5 billion of Retail Co-Payments for 2018, 2017 and 2016, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information about Retail Co-Payments.
(2) | Intersegment eliminations relate to intersegment revenue generating activities that occur between PSS and RLS for 2018, 2017 and 2016. Effective November 28, 2018, intersegment eliminations also relate to intersegment revenue generating activities that occur between HCBS, PSS and/or RLS.
(3) | Corporate/Other segment net investment income for 2018 includes interest income of $536 million related to the proceeds of the $40 billion 2018 Notes. This amount is for the period prior to the close of the Aetna Acquisition, which occurred on November 28, 2018.
(4) | RLS operating income for 2018, 2017 and 2016 includes $7 million, $34 million and $281 million, respectively, of acquisition-related integration costs. The integration costs in 2018 and 2017 are related to the acquisition of Omnicare. The integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacy and clinic businesses of Target. RLS operating income for 2018 and 2017 also includes goodwill impairment charges of $6.1 billion related to the LTC reporting unit and $181 million related to the RxCrossroads reporting unit, respectively. In addition, RLS operating income for 2017 and 2016 includes $215 million and $34 million, respectively, of charges associated with store rationalization and asset impairment charges in connection with planned store closures related to the Company’s enterprise streamlining initiative. RLS operating income for 2018 also includes a $43 million loss on impairment of long-lived assets primarily related to the impairment of property and equipment and an $86 million loss on the divestiture of the Company’s RxCrossroads subsidiary.
(5) | Corporate/Other segment operating loss for 2018, 2017 and 2016 includes $485 million, $40 million and $10 million, respectively, of divestiture and acquisition-related transaction and integration costs included in operating expenses in the consolidated statements of operations. The transaction and integration costs in 2018 are related to the acquisitions of Aetna and Omnicare. The transaction and integration costs in 2017 are related to the acquisitions of Aetna and Omnicare and the divestiture of RxCrossroads. The integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacy and clinic businesses of Target.
(6) | PSS operating income for 2016 includes the reversal of an accrual of $88 million in connection with a legal settlement.
(7) | Amounts revised to reflect the reclassification of interest income from interest expense, net to net investment income within total revenues to conform with insurance company presentation which increased total revenues and operating income by $21 million and $20 million in 2017 and 2016, respectively.
Schedule of segment financial information adjusted | Segment financial information for the years ended December 31, 2017 and 2016, have been retrospectively adjusted to reflect this change to the Company’s cost allocation methodology and net investment income presentation as shown below:
| Year Ended December 31, 2017
| Pharmacy |  | Retail/ |  | Corporate/ |  | Intersegment |  | Consolidated
In millions | Services |  | LTC |  | Other |  | Eliminations |  | Totals
Revenues, as previously reported | $ | 130,596 |  |  | $ | 79,398 |  |  | $ | — |  |  | $ | (25,229 | ) |  | $ | 184,765 |
Adjustments | 5 |  |  | — |  |  | 16 |  |  | — |  |  | 21 |
Revenues, as adjusted | $ | 130,601 |  |  | $ | 79,398 |  |  | $ | 16 |  |  | $ | (25,229 | ) |  | $ | 184,786 |
Cost of products sold (1) | $ | 121,746 |  |  | $ | 56,081 |  |  | $ | — |  |  | $ | (24,417 | ) |  | $ | 153,410 |
Adjustments | 53 |  |  | (15 | ) |  | — |  |  | — |  |  | 38 |
Cost of products sold | $ | 121,799 |  |  | $ | 56,066 |  |  | $ | — |  |  | $ | (24,417 | ) |  | $ | 153,448 |
Benefit costs (1) | $ | 2,810 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 2,810 |
Adjustments | — |  |  | — |  |  | — |  |  | — |  |  | — |
Benefit costs | $ | 2,810 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 2,810 |
Operating expenses, as previously reported | $ | 1,285 |  |  | $ | 16,848 |  |  | $ | 966 |  |  | $ | (71 | ) |  | $ | 19,028 |
Adjustments | 50 |  |  | (74 | ) |  | (14 | ) |  | — |  |  | (38 | )
Operating expenses, as adjusted | $ | 1,335 |  |  | $ | 16,774 |  |  | $ | 952 |  |  | $ | (71 | ) |  | $ | 18,990 |
Operating income (loss), as previously reported | $ | 4,755 |  |  | $ | 6,469 |  |  | $ | (966 | ) |  | $ | (741 | ) |  | $ | 9,517 |
Adjustments | (98 | ) |  | 89 |  |  | 30 |  |  | — |  |  | 21 |
Operating income (loss), as adjusted | $ | 4,657 |  |  | $ | 6,558 |  |  | $ | (936 | ) |  | $ | (741 | ) |  | $ | 9,538 |
_____________________________________________ (1) The total of cost of products sold and benefit costs previously was reported as cost of revenues.
| Year Ended December 31, 2016
| Pharmacy |  | Retail/ |  | Corporate/ |  | Intersegment |  | Consolidated
In millions | Services |  | LTC |  | Other |  | Eliminations |  | Totals
Revenues, as previously reported | $ | 119,963 |  |  | $ | 81,100 |  |  | $ | — |  |  | $ | (23,537 | ) |  | $ | 177,526 |
Adjustments | 2 |  |  | — |  |  | 18 |  |  | — |  |  | 20 |
Revenues, as adjusted | $ | 119,965 |  |  | $ | 81,100 |  |  | $ | 18 |  |  | $ | (23,537 | ) |  | $ | 177,546 |
Cost of products sold (1) | $ | 111,883 |  |  | $ | 57,362 |  |  | $ | — |  |  | $ | (22,755 | ) |  | $ | 146,490 |
Adjustments | 66 |  |  | (23 | ) |  | — |  |  | — |  |  | 43 |
Cost of products sold | $ | 111,949 |  |  | $ | 57,339 |  |  | $ | — |  |  | $ | (22,755 | ) |  | $ | 146,533 |
Benefit costs (1) | $ | 2,179 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 2,179 |
Adjustments | — |  |  | — |  |  | — |  |  | — |  |  | — |
Benefit costs | $ | 2,179 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 2,179 |
Operating expenses, as previously reported | $ | 1,225 |  |  | $ | 16,436 |  |  | $ | 891 |  |  | $ | (61 | ) |  | $ | 18,491 |
Adjustments | 42 |  |  | (112 | ) |  | 27 |  |  | — |  |  | (43 | )
Operating expenses, as adjusted | $ | 1,267 |  |  | $ | 16,324 |  |  | $ | 918 |  |  | $ | (61 | ) |  | $ | 18,448 |
Operating income (loss), as previously reported | $ | 4,676 |  |  | $ | 7,302 |  |  | $ | (891 | ) |  | $ | (721 | ) |  | $ | 10,366 |
Adjustments | (106 | ) |  | 135 |  |  | (9 | ) |  | — |  |  | 20 |
Operating income (loss), as adjusted | $ | 4,570 |  |  | $ | 7,437 |  |  | $ | (900 | ) |  | $ | (721 | ) |  | $ | 10,386 |
_____________________________________________ (1) The total of cost of products sold and benefit costs previously was reported as cost of revenues.

X
- Definition Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22663-107794 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22644-107794 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22658-107794 + Details
Name: | us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration